Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Ready-made Chinese herbal medicine (RMCHM) is one of the most common types of synergistic herbal medicine used worldwide. It is based on composite herbal formulae (CHF), which makes quality control of this kind of traditional Chinese medicine (TCM) difficult, let alone distinguishing the good from the bad. Taking Niuhuang Qingwei Pills (NHQWP) as an example, this study reported the development of a novel principle of analysis of multiple components in RMCHM. Experimental procedures involved the selection of high-quality Chinese materia medica (CMM, individual medicinal plant parts used in the NHQWP) to prepare three batches of TCM reference drugs (TCMRD). Pure compounds of the active ingredients identified in the herbal formula including berberine hydrochloride, geniposide, forsythiaside A, 3,5-O-dicaffeoyl quinic acid, hesperidin, baicalin, glycyrrhizic acid, and chrysophanol in the three TCMRDs were analyzed as well as those in 49 batches of commercial products from 18 manufacturers by ultra-performance liquid chromatography (UPLC) method combined with wavelength switching. Using the TCMRD as the scientific ruler, quality grade specifications of NHQWP were proposed by comprehensive analysis of multiple components. Accordingly, 13, 28, and 8 batches of samples were primarily rated as first-grade, second-grade, and unqualified, respectively.

Details

Title
Quality Grade Evaluation of Niuhuang Qingwei Pills Based on UPLC and TCM Reference Drug—A Novel Principle of Analysis of Multiple Components in Ready-Made Chinese Herbal Medicine
Author
Li-Xing, Nie 1 ; Yi-Fan Zha 2 ; Jian-Dong, Yu 1 ; Kang, Shuai 2 ; Dai, Zhong 1 ; Shuang-Cheng, Ma 1 ; Chan, Kelvin 3   VIAFID ORCID Logo 

 National Institutes for Food and Drug Control, National Medical Products Administration, Beijing 100050, China; [email protected] (L.-X.N.); [email protected] (Y.-F.Z.); [email protected] (J.-D.Y.); [email protected] (S.K.); [email protected] (Z.D.); WHO Collaborating Center for Herbal Medicine (CHN-139), Beijing 100050, China 
 National Institutes for Food and Drug Control, National Medical Products Administration, Beijing 100050, China; [email protected] (L.-X.N.); [email protected] (Y.-F.Z.); [email protected] (J.-D.Y.); [email protected] (S.K.); [email protected] (Z.D.) 
 Centre for Natural Products Discovery, School of Pharmacy & Biomolecular Science, Liverpool John Moores University, Liverpool L3 3AF, UK; NICM Health Research Institute, Western Sydney University, Sydney 1793, Australia 
First page
1166
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
22279717
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2679825599
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.